TransCode Therapeutics Inc (RNAZ) Actualités

Form 8-K - Current report

TransCode Therapeutics, Inc. Announces Results of Special Meeting

TransCode Therapeutics, Inc. Announces Results of Special Meeting PR Newswire BOSTON, Feb. 25, 2025 BOSTON, Feb. 25, 2025 /PRNewswire/...

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special...

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical...

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements PR...

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form PRE 14A - Other preliminary proxy statements

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary...

Form EFFECT - Notice of Effectiveness

Form D - Notice of Exempt Offering of Securities

Form S-1 - General form for registration of securities under the Securities Act of 1933